Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Cell Death Discovery|June 20, 2022
Promising prognostic value of Transglutaminase type 2 and its correlation with tumor-infiltrating immune cells in skin cutaneous melanomaSilvia Muccioli, Roberto Ciaccio, Valentina Brillo, et al.Life (Basel, Switzerland)|April 30, 2021
Mitochondrial Dynamics, ROS, and Cell Signaling: A Blended OverviewValentina Brillo, Leonardo Chieregato, Luigi Leanza, et al.International Journal of Molecular Sciences|April 30, 2021
From Channels to Canonical Wnt Signaling: A Pathological PerspectiveSilvia Muccioli, Valentina Brillo, Leonardo Chieregato, et al.Pharmacological Research|December 21, 2020
Mitochondrial dysfunction interferes with neural crest specification through the FoxD3 transcription factorRoberto Costa, Silvia Muccioli, Valentina Brillo, et al.International Journal of Molecular Sciences|March 13, 2024
The Role of Transglutaminase 2 in Cancer: An UpdateElisabetta Zaltron, Federica Vianello, Alessia Ruzza, et al.Cells|December 15, 2019
Rewiring of Lipid Metabolism and Storage in Ovarian Cancer Cells after Anti-VEGF TherapyMatteo Curtarello, Martina Tognon, Carolina Venturoli, et al.Pharmacological Research|February 21, 2026
Tumor-specific targeting of a mitochondrial Kv1.3 channel inhibitor through conjugation to gastrin/cholecystokinin B receptor ligand strongly reduces pancreatic ductal adenocarcinoma in orthotopic modelsSofia Parrasia, Carlotta Paoli, Tatiana Varanita, et al.Journal of Experimental & Clinical Cancer Research : CR|August 7, 2023
Anti-VEGF therapy selects for clones resistant to glucose starvation in ovarian cancer xenograftsDaniele Boso, Martina Tognon, Matteo Curtarello, et al.Cell Death & Disease|October 29, 2023
Transglutaminase Type 2-MITF axis regulates phenotype switching in skin cutaneous melanomaSilvia Muccioli, Valentina Brillo, Tatiana Varanita, et al.Pageof 1